8-K: N2OFF Loans $372K to MitoCareX for Acquisition

N2OFF, Inc. has provided a $372,000 loan to MitoCareX Bio Ltd. to finance its operations ahead of a planned acquisition, subject to N2OFF shareholder approval.

Summary

• N2OFF, Inc. entered into a Fourth Loan Agreement with MitoCareX Bio Ltd. and L.I.A. Pure Capital Ltd. on August 17, 2025.
• N2OFF will loan MitoCareX $372,000 (the Principal) with interest accruing at an annual rate based on the USD exchange rate fluctuation plus 3%, as per Section 3(j) of the Israel Income Tax Ordinance.
• The loan has a six-month term, with Principal and accrued interest due at maturity.
• The purpose of the loan is to assist MitoCareX with financing its ongoing costs and obligations until the closing of a previously announced acquisition.
• N2OFF plans to acquire all ordinary shares of MitoCareX, making it a wholly-owned subsidiary, a transaction subject to N2OFF's stockholder approval.
• L.I.A. Pure Capital Ltd. has guaranteed the repayment of the loan.
• If MitoCareX becomes a subsidiary of N2OFF, any outstanding loan amount will be deducted from future allocations by N2OFF to MitoCareX during the first year following the transaction.
• The loan will be disbursed in tranches: $200,000 immediately on August 17, 2025, $86,000 on September 15, 2025, and $86,000 on October 15, 2025.

Sentiment

Score: 6

Explanation: The filing indicates a positive step towards completing a strategic acquisition by providing necessary bridge financing, which is guaranteed. However, the acquisition itself is still subject to shareholder approval, introducing a degree of uncertainty.

Positives

• Provides necessary bridge financing for MitoCareX, ensuring its operational continuity until the planned acquisition by N2OFF closes.
• The loan repayment is guaranteed by L.I.A. Pure Capital Ltd., reducing N2OFF's credit risk.
• Facilitates the strategic acquisition of MitoCareX, which is expected to become a wholly-owned subsidiary of N2OFF.

Negatives

• The loan is contingent on a future event (the acquisition closing), which requires N2OFF's stockholder approval, introducing uncertainty.
• If the acquisition does not close, the loan terms regarding deduction from future allocation would not apply, potentially requiring direct repayment.

Risks

• The closing of the acquisition of MitoCareX by N2OFF is subject to various terms and conditions, including N2OFF's stockholder approval, which may not be obtained.
• Failure to close the acquisition could impact the repayment mechanism of the loan, requiring direct repayment rather than deduction from future allocations.
• MitoCareX's ability to meet its ongoing costs and obligations is dependent on this loan, indicating potential financial strain prior to the acquisition.

Future Outlook

The loan is intended to bridge MitoCareX's financial needs until the closing of its acquisition by N2OFF, which is contingent on N2OFF's stockholder approval.

Management Comments

• The purpose of the Fourth Loan Agreement is to assist MitoCareX with financing its ongoing costs and obligations until the closing of the Agreement has occurred.

Industry Context

This transaction represents a common strategy in the biotechnology and pharmaceutical sectors where larger companies provide bridge financing to smaller, target companies to sustain operations and facilitate due diligence or regulatory processes leading up to an acquisition. It reflects N2OFF's commitment to the pending acquisition of MitoCareX, a private Israeli company, indicating potential expansion or diversification within its strategic focus.

Related Party Transactions

• N2OFF, Inc. (Lender) is providing a loan to MitoCareX Bio Ltd. (Borrower), a company N2OFF intends to acquire and make a wholly-owned subsidiary. This constitutes a related party transaction in the context of the pending acquisition.

Stakeholder Impact

• Shareholders (N2OFF): Required to approve the acquisition, which the loan facilitates. The loan represents a deployment of capital.
• MitoCareX Bio Ltd.: Receives crucial financing to cover ongoing costs and obligations, ensuring operational stability until the acquisition closes.
• L.I.A. Pure Capital Ltd.: Acts as a guarantor for the loan, assuming financial risk for repayment.
• Sellers (SciSparc Ltd., Dr. Alon Silberman, Prof. Ciro Leonardo Pierri): The loan helps maintain the value and operational status of MitoCareX until the sale of their shares to N2OFF is finalized.

Next Steps

• N2OFF's stockholders must approve the acquisition of MitoCareX.
• Closing of the Securities Purchase and Exchange Agreement for the acquisition of MitoCareX.
• Repayment of the $372,000 loan by MitoCareX to N2OFF within six months, or deduction from future allocations if the acquisition closes.

Key Dates

Recommendation

This filing details a bridge loan for a pending acquisition, not a standalone financial performance. While it's a necessary step to facilitate a strategic move, the ultimate success and impact depend on the acquisition's completion and its long-term value. Without further details on the strategic rationale or financial projections of the acquisition, a 'hold' position is prudent, awaiting the outcome of the shareholder vote and further integration details.

Keywords

N2OFF, MitoCareX, Loan Agreement, Acquisition, Bridge Financing, Corporate Governance, SEC Filing, 8-K, Israel, Biotechnology, M&A, Shareholder Approval